Shattuck Labs, Inc.
STTK Healthcare Biotechnology
In the quarter to June 2026, revenue fell 10.3%, EPS grew 50.0% and free cash flow grew 1.01%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow STTK
Shattuck Labs, Inc. (STTK) Altman Z-score
Shattuck Labs, Inc.'s Altman Z-score for fiscal 2025 is 10.16, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 10.16 | 14.74 |
| FY2024 | −4.57 | (13.25) |
| FY2023 | 8.68 | 8.89 |
| FY2022 | −0.21 | (8.33) |
| FY2021 | 8.12 | (4.86) |
| FY2020 | 12.98 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.83 | — | 0.99 | |
| Retained earnings / total assets | (4.73) | — | −6.62 | |
| EBIT / total assets | (0.57) | — | −1.87 | |
| Market value of equity / total liabilities | 29.41 | — | 17.65 | |
| Sales / total assets | 0.01 | — | 0.01 | |
| Altman Z-score | Safe zone | 10.16 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −3.77 | ||
Z and Z″ put Shattuck Labs, Inc. in different zones: safe zone by Z, distress zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| STTK Shattuck Labs, Inc. | 10.2× |
| SGMT Sagimet Biosciences Inc. compare | 2.5× |
| DBVT DBV Technologies S.A. compare | 1.3× |
| VALN Valneva SE Sponsored ADR compare | −0.5× |
| PBYI Puma Biotechnology, Inc. compare | −4.2× |
| SLN Silence Therapeutics PLC Sponsored ADR compare | −4.8× |
| FTH Faeth Therapeutics, Inc. compare | — |
| VECT VectivBio Holding AG compare | — |
| DRUG Bright Minds Biosciences Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets